SCHEMBL30983449

SCHEMBL30983449

CC1(Oc2ncnc3c2nc(-c2ccc(OCC(=O)NCCO)cc2Cl)n3Cc2ccccc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.42
▸ ACACA Q13085 1/20 0.38
▸ PDK2 Q15119 1/20 0.37
▸ ACHE P22303 6/20 0.37
▸ BCHE P06276 2/20 0.37
▸ FAAH O00519 5/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ HTT P42858 2/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NR2E3 Q9Y5X4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983512 0.91 KMT2A (0.36) PDK2KMT2ASMN1; SMN2PIK3CDMEN1
SCHEMBL30983397 0.90 PIK3CD (0.34) KMT2ASMN1; SMN2PIK3CDMEN1
SCHEMBL30983954 0.89 PLA2G2A (0.39) KMT2AKDM4EPIK3CDHTTADORA2B
SCHEMBL31269166 0.89 ALDH1A1 (0.40) ALDH1A1ACACAPDK2KMT2ASMN1; SMN2
SCHEMBL30983924 0.88 PLA2G2A (0.38) KMT2APIK3CD
SCHEMBL30984034 0.87 PIK3CD (0.37) ALDH1A1KMT2AMAPTKDM4EPIK3CD
SCHEMBL30983502 0.87 NPC1 (0.38) ALDH1A1PDK2KMT2ASMN1; SMN2KDM4E
SCHEMBL30983529 0.86 PDK2 (0.38) ALDH1A1PDK2KMT2ALMNAKDM4E
SCHEMBL30983424 0.85 HTR1D (0.43) ALDH1A1KMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL31321937 0.85 PLA2G2A (0.40) PDK2PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB ALDH1A1 3824/4885ACACA 3088/4885PDK2 1482/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB ALDH1A1 3824/4885ACACA 3088/4885PDK2 1482/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB ALDH1A1 3824/4885ACACA 3088/4885PDK2 1482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback